Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Opinion Article

Personalized Medicine: Advanced Treatment Strategies to Revolutionize Healthcare

Author(s): Arun Kumar Singh, Rishabha Malviya* and Swati Verma

Volume 15, Issue 2, 2023

Published on: 09 December, 2022

Page: [101 - 104] Pages: 4

DOI: 10.2174/2589977515666221104152641

Price: $65

conference banner
Abstract

Personalized medicine (PM) is about developing an individualized approach to each patient's illness. Understanding how a patient's genomic portfolio renders them prone to various diseases may be enhanced by discovering genetic, epigenetic, and medical evidence. Medical therapy that is safe and effective for specific individuals may be predicted using the PM approach, which is a complete expansion of an older methodology (One-Size-Fits-All). Patient’s well-being and longevity may improve and costs are reduced if PM is used. Using existing biomarkers and early genome and epigenomic processes to better understand PM may lead to earlier diagnosis of the disease, including carcinogenesis. A key focus of the PM technique is preventative medicine, which emphasizes proactive actions rather than depending only on reactive ones. More intrusive procedures may be avoided or postponed using this technique, resulting in a higher quality of life and lower financial burdens for patients. End-of-life care costs are putting a strain on governmentfunded healthcare systems across the globe, notably in the United States. When used in conjunction with present treatments, PM may help them work better and lessen the disadvantages of just non-PM methods. Using genetic profiling, doctors may choose a drug based on a participant's genetic profile that minimizes unwanted side effects and ensures a better result while also being less costly than a 'trial-and-error' approach to sickness treatment. The less effective non- PM ('trial-and-error') strategy leads to drug toxicity, severe adverse effects, reactive treatment, and misdiagnosis. PM and proactive therapeutic regimens should be used more often to save costs and enhance overall well-being.

Next »
[1]
Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine: Part 1: Evolution and development into theranostics. P&T 2010; 35(10): 560-76.
[PMID: 21037908]
[2]
Vogenberg FR, Barash CI, Pursel M. Personalized medicine: Part 2: Ethical, legal, and regulatory issues. P&T 2010; 35(11): 624-42.
[PMID: 21139819]
[3]
Jakka S, Rossbach M. An economic perspective on personalized medicine. HUGO J 2013; 7(1): 1.
[http://dx.doi.org/10.1186/1877-6566-7-1]
[4]
Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005; 14 (Suppl. 2): R207-14.
[http://dx.doi.org/10.1093/hmg/ddi261] [PMID: 16244319]
[5]
Težak Ž, Kondratovich MV, Mansfield EUS. FDA and personalized medicine: In vitro diagnostic regulatory perspective. Per Med 2010; 7(5): 517-30.
[http://dx.doi.org/10.2217/pme.10.53] [PMID: 29776248]
[6]
Vu T, Claret FX. Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front Oncol 2012; 2: 62.
[http://dx.doi.org/10.3389/fonc.2012.00062] [PMID: 22720269]
[7]
Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, et al. Active surveillance for prostate cancer. Int J Urol 2016; 23(3): 211-8.
[http://dx.doi.org/10.1111/iju.13016] [PMID: 26621054]
[8]
Miedany YE. MABS: Targeted therapy tailored to the patient’s need. Br J Nurs 2015; 24(Sup16a): S4-S13.
[http://dx.doi.org/10.12968/bjon.2015.24.Sup16a.S4] [PMID: 26946646]
[9]
Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy 2011; 31(8): 813-28.
[http://dx.doi.org/10.1592/phco.31.8.813] [PMID: 21923608]
[10]
Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 2013; 10(10): 957-63.
[http://dx.doi.org/10.1038/nmeth.2649] [PMID: 24076990]
[11]
Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature 2016; 539(7630): 479.
[http://dx.doi.org/10.1038/nature.2016.20988] [PMID: 27882996]
[12]
Reardon S. First CRISPR clinical trial gets green light from US panel. Nature News. Available from: http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-usupanel-1.2013710.1038/nature.2016.20137 (Accessed on: Oct 8, 2016).
[13]
Kulkarni A, Padilla N. A strategist's guide to personalized medicine. Strategy and Business 2014; Available form: https://www.strategy-business.com/article/00131
[14]
Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363(4): 301-4.
[http://dx.doi.org/10.1056/NEJMp1006304] [PMID: 20551152]
[15]
Association of the British Pharmaceutical Industry. The stratification of disease for personalised medicines. Available from: http://www.abpi.org.uk/our-work/library/medical-disease/Pages/personalised-medicines.aspx
[16]
Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov 2018; 17(3): 183-96.
[http://dx.doi.org/10.1038/nrd.2017.226] [PMID: 29217837]
[17]
Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17(4): 223-38.
[http://dx.doi.org/10.1038/nrc.2017.7] [PMID: 28233803]
[18]
Jamal-Hanjani M, Hackshaw A, Ngai Y, et al. Tracking genomic cancer evolution for precision medicine: The lung TRACERx study. PLoS Biol 2014; 12(7)e1001906
[http://dx.doi.org/10.1371/journal.pbio.1001906] [PMID: 25003521]
[19]
Hood L, Galas D. The digital code of DNA. Nature 2003; 421(6921): 444-8.
[http://dx.doi.org/10.1038/nature01410] [PMID: 12540920]
[20]
Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10): 665-74.
[http://dx.doi.org/10.1097/GIM.0b013e31815699d0] [PMID: 18073579]
[21]
Snyderman R. The Case for Personalized Medicine. (3rd ed.). Washington, DC 2011; pp. 1-32.
[22]
U.S. Food and Drug Administration. Paving way for personalized medicine: FDA's role in a new era of medical product development. Available from: http://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421 (Accessed on: Jan 10, 2014).

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy